Anzeige
Mehr »
Login
Mittwoch, 12.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
US-Biotech-Firma sorgt für Furore - steckt hier die Zukunft der Krebsheilung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4098S | ISIN: US6963894026 | Ticker-Symbol: 7NS0
NASDAQ
11.02.25
21:57 Uhr
1,130 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PALISADE BIO INC Chart 1 Jahr
5-Tage-Chart
PALISADE BIO INC 5-Tage-Chart

Aktuelle News zur PALISADE BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiPALI-Aktie stürzt auf 52-Wochen-Tief von 1,15 US-Dollar2
PALISADE BIO Aktie jetzt für 0€ handeln
MoPalisade Bio, Inc.: Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis99Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company...
► Artikel lesen
03.02.PALI-Aktie erreicht 52-Wochen-Tief bei 1,32 US-Dollar2
29.01.Palisade Bio, Inc.: Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress2
22.01.PALI-Aktie fällt auf 52-Wochen-Tief und erreicht 1,34 US-Dollar2
16.01.Palisade Bio reports positive data for UC drug trial2
16.01.Palisade Bio, Inc.: Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis97Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability...
► Artikel lesen
03.01.Palisade Bio, Inc.: Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)147Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing...
► Artikel lesen
17.12.24Palisade Bio, Inc.: Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board6
16.12.24PALISADE BIO, INC. - 8-K, Current Report-
13.12.24Palisade Bio, Inc.: Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules5
12.12.24What's Going On With Palisade Bio Stock On Thursday?5
12.12.24Palisade Bio, Inc.: Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules1
12.12.24Pre-market Movers: Palisade Bio, Keros Therapeutics, Trevi Therapeutics, Siyata Mobile, Samfine Creation642SAN JOSE (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.45 A.M. ET).In the Green Palisade Bio, Inc. (PALI) is up over 110% at $2.95. Trevi...
► Artikel lesen
10.12.24PALI-Aktie fällt auf 52-Wochen-Tief von 1,68 US-Dollar6
05.12.24PALISADE BIO, INC. - S-1/A, General form for registration of securities1
03.12.24PALI-Aktie stürzt auf 52-Wochen-Tief von 2,13 US-Dollar2
03.12.24Palisade Bio, Inc.: Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects144First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) ("Palisade," "Palisade...
► Artikel lesen
21.11.24PALISADE BIO, INC. - S-1/A, General form for registration of securities-
21.11.24Palisade Bio, Inc.: Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)1
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1